Successful generic drug production of world’s latest Covid-19 treatment medicine called PAXLOVID (Nirmatrelvir 150mg; Ritonavir 100mg), produced under the name “PACLOVID” domestically at our pharmaceutical factory: Pacific Medical Industries Ltd (PMI)
Pacific Medical Industries (PMI) is pleased to announce the approval of PACLOVID (Nirmatrelvir 150mg; Ritonavir 100mg) by the Myanmar FDA with recommendation letter no. 2308ND012 for the use of PACLOVID in the mild to moderate coronavirus (COVID-19) in adults. PACLOVID (Nirmatrelvir 150gm; Ritonavir 100mg) is globally recognized as the latest and effective formulation against the fight against COVID-19. It is strongly recommended for patients with non-severe COVID-19 who are at highest risk of developing severe disease and hospitalization, such as unvaccinated, older, or immunosuppressed patients according to WHO data.
Nirmatrelvir 150gm; Ritonavir 100mg can effectively reduce the hospitalizations and can reduce the covid deaths in at-risk by up to 90 percent when taken in the first few days after against Delta and Omicron (Laboratory test) variant and it can be recommended for pediatric patients (12 years older & older weighing at least 40kg) (Reference: New COVID pill: EMA gives Pfizer's antiviral drug Paxlovid the green light to be used in the EU | Euronews)
The PACLOVID (Nirmatrelvir 150mg, Ritonavir 100mg) was successfully manufactured by the PMI factory which deploys the world-class pharmaceutical manufacturing equipment in its western pharmaceutical manufacturing facility that produces the pharmaceutical products with the quality adhere to the World Health Organization (WHO)’s Good Manufacturing Practice (WHO’s cGMP) standards. In addition, this facility also obtained the ISO/IEC 17025:2017 Certificate from ANAB, (ANSI National Accreditation Board, USA) for ISO Testing and Calibration Laboratories for the competence, impartiality, and consistent operation of laboratories, which includes management and technical requirements that enable a testing or calibration laboratory to claim their technical competency. Secondly, having accreditation by regulatory bodies certifies that the results are consistent, accurate and are generated using industry-standard protocols. We are delighted to be the very first privately-owned pharmaceutical factory in Myanmar to achieve the ISO/IEC 17025:2017 Certification. This certification is also obtained by the Myanmar Food and Drugs Administration (Myanmar FDA)’s Pharmaceutical Chemistry Laboratory and the Pacific Medical Industries Ltd., is the second domestic pharmaceutical factory to achieve it after the Myanmar FDA’s facility.
As we always thrive to achieve the domestic production of the international standard quality pharmaceutical products to fulfill the greater healthcare needs of the people of Myanmar, there is potentially the coming wave of COVID-19 pandemic coming to Myanmar and we are ready with the production of the COVID-19 oral medicine with high success rate in treatment regime, the PACLOVID (Nirmatrelvir 150mg; Ritonavir 100mg), and we had obtained the approval from Myanmar FDA.
Pacific Medical Industries has been at the forefront of the fight against COVID-19 in Myanmar, being the first to introduce FAVIPAC 200, 400 (Favipirivir 200mg and 400mg) and MOLNUPAC 200, 400 (Molnupirivir 200mg and 400mg) into the market when the Myanmar people needed it most, followed by the innovative PACLOVID (Nirmatrelvir 150mg; Ritonavir 100mg) which was with high successful rate in the fight against COVID-19. The approval of PACLOVID (Nirmatrelvir 150mg; Ritonavir 100mg) by the Myanmar Food and Drug Administration (FDA) to locally manufacture one of the most effective globally recognized formulation to treat COVID-19 is testament to the objective of PMI in producing cutting-edge medication in a world class facility built to serve the people of Myanmar. Our greatest success is when Myanmar people have locally available access to world class medication. We continue to serve the people of Myanmar through our continued dedication and commitment.
This medicine is prescription only medicine (POM) and please consult with your doctor before using it.